Share on StockTwits

Dr. Reddy’s Laboratories Limited (NYSE:RDY) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, Analyst Ratings Net reports. They currently have a $45.90 price objective on the stock. Zacks‘ price objective points to a potential upside of 6.42% from the stock’s previous close.

Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) traded up 0.26% on Tuesday, hitting $43.24. 127,308 shares of the company’s stock traded hands. Dr. Reddy’s Laboratories Limited has a 52-week low of $31.32 and a 52-week high of $43.81. The stock has a 50-day moving average of $40.74 and a 200-day moving average of $38.29. The company has a market cap of $7.355 billion and a price-to-earnings ratio of 19.50.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an integrated pharmaceutical company focused on providing medicines through its three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment and Proprietary Products segment.

To view Zacks’ full report, visit

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.